• About
• Links
• Contact
• Sitemap
• 

The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

Summary

The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global oncology therapeutics market. The report analyzes the markets for oncology therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis.

Scope

The scope of this report includes:

Annualized market data for the oncology therapeutics market from 2000 to 2008, forecast forward to 2015

Analysis of the leading therapeutic segments including lung cancer, breast cancer, prostate cancer, colorectal cancer and Non-Hodgkin’s Lymphoma.

Analysis of the oncology diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan

Market characterization of the oncology therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns

Key drivers and barriers that have a significant impact on the market

Coverage of pipeline molecules in various phases of drug development

Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, Novartis AG, Sanofi-aventis, Amgen, AstraZeneca, Merck & Co, Pfizer Inc, Celgene Corporation, Bristol-Myers Squibb and Eli Lilly

Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global oncology therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to

Align product portfolio to the markets with high growth potential

Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth

Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety

Develop key strategic initiatives by understanding key focus areas of leading companies

Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

Table of Contents

1 Table of Contents 4

• 1.1 List of Tables 8
• 1.2 List of Figures 10

2 Global Oncology Therapeutics Market: Introduction 13

• 2.1 Report Guidance 14

3 Global Oncology Therapeutics Market: Cancer Epidemiology 15

4 Global Oncology Therapeutics Market: Market Overview 16

• 4.1 Introduction 16
• 4.2 Revenue Forecasts for the Global Oncology Therapeutics Market 18
  • 4.2.1 Sales Value 18
  • 4.2.2 Sales Volume 19
  • 4.2.3 Drug Prices 20
  • 4.2.4 Treatment Usage Patterns 21
• 4.3 Generics in Oncology Therapeutics Market 25
• 4.4 Oncology therapeutics market Drivers 26
  • 4.4.1 Steady Increase in the Ageing Population 26
  • 4.4.2 New Innovative Products in the Pipeline 27
  • 4.4.3 Rapid Uptake of Targeted Therapies in Key Cancer Indications 27
• 4.5 Oncology Therapeutics Market Restraints 27
  • 4.5.1 The US Cancer Incidence Moving Towards a Decelerating Growth Rate 27
  • 4.5.2 Patent Expirations and Entry of Generics Pose as a Severe Threat for Primary Manufacturers 28
  • 4.5.3 Restrictive Pricing and Reimbursement Policies Causing Serious Problems in the Oncology Therapeutics Market Growth 29
  • 4.5.4 More Than 80 Molecules to be Launched Over the Next Seven years - Leading to More Competition 30

5 Global Oncology Therapeutics Market: Pricing and Reimbursement 31

• 5.1 Average Cost of Drug Treatment 31
• 5.2 The US 33
  • 5.2.1 Pricing 33
  • 5.2.2 Medicare Reimbursement on Cancer Drugs 33
• 5.3 Europe 34
  • 5.3.1 Pricing and Reimbursement - Country Analysis 36

6 Global Oncology Therapeutics Market: Geographical Landscape 41

• 6.1 Geographic Break-up 41
• 6.2 The US 42
  • 6.2.1 Sales Value 42
  • 6.2.2 Sales Volume 43
  • 6.2.3 Drug Prices 44
  • 6.2.4 Treatment Usage Patterns 45
• 6.3 Top Five European Countries 49
  • 6.3.1 Sales Value 49
  • 6.3.2 Sales Volume 51
  • 6.3.3 Drug Prices 51
  • 6.3.4 Treatment Usage Patterns 53
• 6.4 Japan 57
  • 6.4.1 Sales Value 57
  • 6.4.2 Sales Volume 58
  • 6.4.3 Drug Prices 59
  • 6.4.4 Treatment Usage Patterns 60

7 Global Oncology Therapeutics Market: Therapeutic Landscape 65

• 7.1 Breast Cancer Therapeutics Market 65
  • 7.1.1 Introduction 65
  • 7.1.2 Sales Value 67
  • 7.1.3 Sales Volume 68
  • 7.1.4 Drug Prices 69
  • 7.1.5 Treatment Usage Patterns 70
• 7.2 Non-Hodgkin’s Lymphoma Therapeutics Market 75
  • 7.2.1 Introduction 75
  • 7.2.2 Sales Value 76
  • 7.2.3 Sales Volume 78
  • 7.2.4 Drug Prices 78
  • 7.2.5 Treatment Usage Patterns 79
• 7.3 Colorectal Cancer Therapeutics Market 83
  • 7.3.1 Introduction 83
  • 7.3.2 Sales Value 87
  • 7.3.3 Sales Volume 88
  • 7.3.4 Drug Prices 89
  • 7.3.5 Treatment Usage Patterns 90
• 7.4 Prostate Cancer Therapeutics Market 94
  • 7.4.1 Introduction 94
  • 7.4.2 Sales Value 96
  • 7.4.3 Sales Volume 97
  • 7.4.4 Drug Prices 98
  • 7.4.5 Treatment Usage Patterns 99
• 7.5 Lung Cancer Therapeutics Market 103
  • 7.5.1 Introduction 103
  • 7.5.2 Sales Value 107
  • 7.5.3 Sales Volume 108
  • 7.5.4 Drug Prices 109
  • 7.5.5 Treatment Usage Patterns 109

8 Global Oncology Therapeutics Market: Pipeline Analysis 115

• 8.1 Introduction 115
  • 8.1.1 R&D Strategies 116
• 8.2 R&D Trends 117
  • 8.2.1 Discovery of Unknown Mutations that Play Key Role in Cancers 117
  • 8.2.2 Pairing Therapeutics and Diagnostics 118
• 8.3 Profiles of Key Late-Stage Drugs 119
  • 8.3.1 Angiogenesis and Multi-Targeted Kinase Inhibitors 119
  • 8.3.2 Hsp90 Inhibitors 121
  • 8.3.3 Insulin-like Growth Factor Receptor Inhibitors 122
  • 8.3.4 Hedgehog Inhibitors 124
  • 8.3.5 Immuno-conjugates 124
• 8.4 Insights into Most Promising Drugs 125
  • 8.4.1 Provenge 125
  • 8.4.2 Denosumab 127
  • 8.4.3 Tasigna 129
  • 8.4.4 Aflibercept 130
  • 8.4.5 Tykerb 131

9 Global Oncology Therapeutics Market: Competitive Landscape 134

• 9.1 Evolving competitive landscape 134
  • 9.1.1 Major players 135
  • 9.1.2 Key areas focused for R&D 135
  • 9.1.3 Challenges faced by brands in marketing the oncology products 136
• 9.2 Market Share Analysis 138
  • 9.2.1 Rituxan, Avastin, Revlimid and Herceptin are expected to lead the market through 2015 139
• 9.3 Roche/Genentech 141
  • 9.3.1 Key Oncology Drugs 142
  • 9.3.2 Key Indications of Interest 145
  • 9.3.3 Pipeline Analysis 146
  • 9.3.4 Key Strategies 148
• 9.4 Novartis 148
  • 9.4.1 Key Oncology Drugs 149
  • 9.4.2 Key Indications of Interest 152
  • 9.4.3 Pipeline Analysis 152
  • 9.4.4 Key Strategies 153
• 9.5 Sanofi-Aventis 155
  • 9.5.1 Key Oncology Drugs 156
  • 9.5.2 Key Indications of Interest 157
  • 9.5.3 Pipeline Analysis 158
  • 9.5.4 Key Strategies 159
• 9.6 Amgen 160
  • 9.6.1 Key Oncology Drugs 161
  • 9.6.2 Key of Indications of Interests 163
  • 9.6.3 Pipeline Analysis 163
  • 9.6.4 Key Strategies 165
• 9.7 Astra Zeneca 165
  • 9.7.1 Key Oncology Drugs 166
  • 9.7.2 Key Indications of Interests 167
  • 9.7.3 Pipeline Analysis 168
  • 9.7.4 Key Strategies 169

10 Global Oncology Therapeutics Market: M&A Landscape 170

• 10.1 Overview 170
  • 10.1.1 Pfizer Acquires Wyeth 170
  • 10.1.2 Roche Acquires Genentech 170
  • 10.1.3 Takeda Pharmaceutical Acquires IDM Pharma 171
  • 10.1.4 EUS Pharma Acquires Cytogen Corporation 171
  • 10.1.5 GlaxoSmithKline Acquires Sirtris Pharmaceuticals 171
  • 10.1.6 GlaxoSmithKline Acquires Bristol-Myers Squibb (Egyptian unit) 171
  • 10.1.7 Pfizer Enters into an Agreement with Aurobindo Pharma and Claris Life Sciences 171
  • 10.1.8 Teva Pharmaceuticals Acquires Barr 171
  • 10.1.9 Sanofi-Aventis Acquires Medley 171
• 10.2 R&D Licensing Agreements 171
  • 10.2.1 Deals by Phase 172
  • 10.2.2 Deals by Geography 172
  • 10.2.3 Deals by Licensing Type 173
  • 10.2.4 Deals by Value ($) 174
  • 10.2.5 Preclinical 174
  • 10.2.6 Phase I 176
  • 10.2.7 Phase II 177
  • 10.2.8 Phase III 178
  • 10.2.9 Approved 180

11 Global Oncology Therapeutics Market: Appendix 182

• 11.1 Research Methodology 182
• 11.2 Geographical Scope 182
• 11.3 Coverage 182
• 11.4 Secondary Research 183
• 11.5 Primary Research 183
• 11.6 Models 183
• 11.7 Forecasts 184
• 11.8 Expert Panel Validation 184
• 11.9 Contact Us 184
• 11.10 Disclaimer 184

1.1 List of Tables

• Table 1: Oncology Therapeutics Market, Global, Revenue Forecasts ($ m), 2000-2008 17
• Table 2: Oncology Therapeutics Market, Global, Revenue Forecasts ($ m), 2008-2015 17
• Table 3: Oncology Therapeutics Market, Global, Sales Volume (million), 2000-2008 18
• Table 4: Oncology Therapeutics Market, Global, Sales Volume (million), 2009-15 18
• Table 5: Oncology Therapeutics Market, Global, Average Cost per Dose ($), 2000-2008 19
• Table 6: Oncology Therapeutics Market, Global, Average Cost per Dose ($), 2008-2015 19
• Table 7: Oncology Therapeutics Market, Global, Treatment Usage Patterns, Historic 2000-2008 20
• Table 8: Oncology Therapeutics Market, Global, Treatment Usage Patterns, Forecasts 2008-2015 21
• Table 9: Oncology Therapeutics Market, Global, Generics Sales Forecast, 2008-2015 25
• Table 10: Oncology Therapeutics Market, The US, Major Drug Patent Expirations, 2009-19 28
• Table 11: Oncology Therapeutics, Global, Annual Cost of Therapy ($), 2000-2008 31
• Table 12: Oncology Therapeutics, Global, Annual Cost of Therapy ($), 2008-2015 31
• Table 13: Direct Medical Costs for Cancer Care in Select European Countries – 2008 33
• Table 14: Reimbursement Rates based on Pharamco-economic Evaluation – 2008 37
• Table 15: Italy Reimbursement Coverage System – 2008 38
• Table 16: Spain Pharmaceutical Pricing System – 2008 39
• Table 17: Italy Reimbursement Coverage System – 2008 39
• Table 18: Oncology Therapeutics Market, Global, Revenue Break-up by Geography ($ m), 2000-2008 40
• Table 19: Oncology Therapeutics Market, Global, Revenue Break-up by Geography ($ m), 2008-2015 41
• Table 20: Oncology Therapeutics Market, The US, Revenue Forecasts ($ m), 2000-2008 42
• Table 21: Oncology Therapeutics Market, The US, Revenue Forecasts ($ m), 2008-2015 42
• Table 22: Oncology Therapeutics Market, The US, Volume Forecasts (million), 2000-2008 43
• Table 23: Oncology Therapeutics Market, The US, Volume Forecasts (million), 2008-2015 43
• Table 24: Oncology Therapeutics Market, The US, Average Cost per Dose ($), 2000-2008 44
• Table 25: Oncology Therapeutics Market, The US, Average Cost per Dose ($), 2008-2015 44
• Table 26: Oncology Therapeutics Market, The US, Treatment Usage Patterns, 2000-2008 45
• Table 27: Oncology Therapeutics Market, The US, Treatment Usage Patterns, 2008-2015 45
• Table 28: Oncology Therapeutics Market, Europe, Revenue Forecasts ($ m), 2000-2008 49
• Table 29: Oncology Therapeutics Market, Europe, Revenue Forecasts ($ m), 2008-2015 49
• Table 30: Oncology Therapeutics Market, Europe, Volume Forecasts (million), 2000-2008 50
• Table 31: Oncology Therapeutics Market, Europe, Volume Forecasts (million), 2008-2015 50
• Table 32: Oncology Therapeutics Market, Europe, Average Cost per Dose ($), 2000-2008 51
• Table 33: Oncology Therapeutics Market, Europe, Average Cost per Dose ($), 2008-2015 52
• Table 34: Oncology Therapeutics Market, Europe, Treatment Usage Patterns, 2000-2008 52
• Table 35: Oncology Therapeutics Market, Europe, Treatment Usage Patterns, 2008-2015 53
• Table 36: Oncology Therapeutics Market, Japan, Revenue ($ bn), 2000-2008 57
• Table 37: Oncology Therapeutics Market, Japan, Revenue ($ bn), 2008-2015 57
• Table 38: Oncology Therapeutics Market, Japan, Volume Forecasts (million), 2000-2008 58
• Table 39: Oncology Therapeutics Market, Japan, Volume Forecasts (million), 2008-2015 58
• Table 40: Oncology Therapeutics Market, Japan, Average Cost per Dose ($), 2000-2008 59
• Table 41: Oncology Therapeutics Market, Japan, Average Cost per Dose ($), 2009-15 59
• Table 42: Oncology Therapeutics Market, Japan, Treatment Usage Patterns, 2000-2008 60
• Table 43: Oncology Therapeutics Market, Japan, Treatment Usage Patterns, 2008-2015 60
• Table 44: Breast Cancer Therapeutics Market, Global, Cancer Categorized by Disease Stage 65
• Table 45: Breast Cancer Therapeutics Market, Global, Revenue ($ bn), 2000-2008 67
• Table 46: Breast Cancer Therapeutics Market, Global, Revenue ($ bn), 2008-2015 67
• Table 47: Breast Cancer Therapeutics Market, Global, Volume (million), 2000-2008 68
• Table 48: Breast Cancer Therapeutics Market, Global, Volume (million), 2008-2015 68
• Table 49: Breast Cancer Therapeutics Market, Global, Average Cost per Dose ($), 2000-2008 69
• Table 50: Breast Cancer Therapeutics Market, Global, Average Cost per Dose ($), 2008-2015 69
• Table 51: Breast Cancer Therapeutics Market, Global, Usage Patterns, 2000-2008 70
• Table 52: Breast Cancer Therapeutics Market, Global, Usage Patterns, 2008-2015 71
• Table 53: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, Cancer Categorized by Disease Stage 74
• Table 54: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, Revenue ($ bn), 2000-2008 76
• Table 55: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, Revenue ($ bn), 2008-2015 76
• Table 56: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, Volume (million), 2000-2008 77
• Table 57: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, Volume (million), 2008-2015 77
• Table 58: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, Average Cost per Dose ($), 2000-2008 78
• Table 59: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, Average Cost per Dose ($), 2008-2015 78
• Table 60: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, Usage Patterns, 2000-2008 79
• Table 61: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, Usage Patterns, 2008-2015 80
• Table 62: Colorectal Cancer Therapeutics Market, Global, Cancer Categorized by Disease Stage 84
• Table 63: Colorectal Cancer Therapeutics Market, Global, Revenue ($ bn), 2000-2008 86
• Table 64: Colorectal Cancer Therapeutics Market, Global, Revenue ($ bn), 2008-2015 86
• Table 65: Colorectal Cancer Therapeutics Market, Global, Volume (million), 2000-2008 87
• Table 66: Colorectal Cancer Therapeutics Market, Global, Volume (million), 2008-2015 87
• Table 67: Colorectal Cancer Therapeutics Market, Global, Average Cost per Dose ($), 2000-2008 88
• Table 68: Colorectal Cancer Therapeutics Market, Global, Average Cost per Dose ($), 2008-2015 88
• Table 69: Colorectal Cancer Therapeutics Market, Global, Usage Patterns, 2000-2008 90
• Table 70: Colorectal Cancer Therapeutics Market, Global, Usage Patterns, 2008-2015 90
• Table 71: Prostate Cancer Therapeutics Market, Global, Cancer Categorized by Disease Stage 94
• Table 72: Prostate Cancer Therapeutics Market, Global, Revenue ($ bn), 2000-2008 96
• Table 73: Prostate Cancer Therapeutics Market, Global, Revenue ($ bn), 2008-2015 96
• Table 74: Prostate Cancer Therapeutics Market, Global, Volume (million), 2000-2008 96
• Table 75: Prostate Cancer Therapeutics Market, Global, Volume (million), 2008-2015 97
• Table 76: Prostate Cancer Therapeutics Market, Global, Average Cost per Dose ($), 2000-2008 97
• Table 77: Prostate Cancer Therapeutics Market, Global, Average Cost per Dose ($), 2008-2015 98
• Table 78: Prostate Cancer Therapeutics Market, Global, Usage Patterns, 2000-2008 99
• Table 79: Prostate Cancer Therapeutics Market, Global, Usage Patterns, 2008-2015 99
• Table 80: Lung Cancer Therapeutics Market, Global, Cancer Categorized by Disease Stage 103
• Table 81: Lung Cancer Therapeutics Market, Global, NSCLC Treatment by Stage of the Disease 105
• Table 82: Lung Cancer Therapeutics Market, Global, Revenue ($ bn), 2000-2008 106
• Table 83: Lung Cancer Therapeutics Market, Global, Revenue ($ bn), 2008-2015 107
• Table 84: Lung Cancer Therapeutics Market, Global, Volume (million), 2000-2008 107
• Table 85: Lung Cancer Therapeutics Market, Global, Volume (million), 2008-2015 107
• Table 86: Lung Cancer Therapeutics Market, Global, Average Cost per Dose ($), 2000-2008 108
• Table 87: Lung Cancer Therapeutics Market, Global, Average Cost per Dose ($), 2008-2015 108
• Table 88: Lung Cancer Therapeutics Market, Global, Usage Patterns, 2000-2008 110
• Table 89: Lung Cancer Therapeutics Market, Global, Usage Patterns, 2008-2015 110
• Table 90: Oncology Therapeutics Market, Global, Top 10 Brands’ Sales ($ m), 2006-2008 139
• Table 91: Oncology Therapeutics Market, Global, Roche/Genentech Sales, 2006-2015 141
• Table 92: Oncology Therapeutics Market, Global, Novartis, Sales ($ m), 2006-2015 148
• Table 93: Oncology Therapeutics Market, Global, Sanofi-Aventis, Sales ($ m), 2006-15 155
• Table 94: Oncology Therapeutics Market, Global, Amgen, Sales ($ m), 2006-2015 160
• Table 95: Oncology Therapeutics Market, Global, AstraZeneca, Sales ($ m), 2006-2015 165
• Table 96: Oncology Therapeutics Market, Global, Licensing Agreements for Drugs in the Preclinical Stage, 2008-09 174
• Table 97: Oncology Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase I, 2008-09 175
• Table 98: Oncology Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II, 2008-09 176
• Table 99: Oncology Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III, 2008-09 178
• Table 100: Oncology Therapeutics Market, Global, Licensing Agreements for Approved Drugs, 2008-09 179

1.2 List of Figures

• Figure 1: Global Cancer Incidence by Tumor Type – 2007 15
• Figure 2: Global Cancer Mortality by Tumor Type – 2007 15
• Figure 3: Oncology Therapeutics Market, Global, Drivers and Restraints, 2008 16
• Figure 4: Oncology Therapeutics Market, Global, Revenue Forecasts ($ m), 2000-2015 17
• Figure 5: Oncology Therapeutics Market, Global, Sales Volume (million), 2000-2015 18
• Figure 6: Oncology Therapeutics Market, Global, Average Cost per Dose ($), 2000-2015 19
• Figure 7: Oncology Therapeutics Market, Global, Treatment Usage Patterns, 2000-2015 20
• Figure 8: Oncology Therapeutics Market, Global, Diseased Population, 2000-2015 21
• Figure 9: Oncology Therapeutics Market, Global, Treatment Seeking Population, 2000-2015 22
• Figure 10: Oncology Therapeutics Market, Global, Diagnosis Population, 2000-2015 23
• Figure 11: Oncology Therapeutics Market, Global, Prescription Population, 2000-2015 24
• Figure 12: Oncology Therapeutics Market, Global, Generics Sales Forecast, 2008-2015 24
• Figure 13: Oncology Therapeutics Market, Global, Drivers and Restraints, 2008-2015 25
• Figure 14: Oncology Therapeutics Market, Global, Future Drivers and Restraints of the market, 2015 29
• Figure 15: Oncology Therapeutics, Global, Annual Cost of Therapy ($), 2000-2015 31
• Figure 16: Oncology Therapeutics, The US, Cost of Treatment ($), 2000-2015 32
• Figure 17: Pricing and Reimbursement Trends of Top Five Countries in the EU – 2008 34
• Figure 18: Oncology Therapeutics, Top Five Countries in the EU , Cost of Treatment ($), 2000-2015 34
• Figure 19: UK NICE Patients Access Schemes by Type 36
• Figure 20: Oncology Therapeutics Market, Global, Revenue Break-up by Geography ($ m), 2000-2015 40
• Figure 21: Oncology Therapeutics Market, Global, Segmentation by Geography – 2008 & 2015 41
• Figure 22: Oncology Therapeutics Market, The US, Revenue Forecasts ($ m), 2000-2015 42
• Figure 23: Oncology Therapeutics Market, The US, Volume Forecasts (million), 2000-2015 43
• Figure 24: Oncology Therapeutics Market, The US, Average Cost per Dose ($), 2000-2015 44
• Figure 25: Oncology Therapeutics Market, The US, Treatment Usage Patterns, 2000-2015 45
• Figure 26: Oncology Therapeutics Market, the US, Diseased Population, 2000-2015 46
• Figure 27: Oncology Therapeutics Market, the US, Treatment Seeking Population, 2000-2015 46
• Figure 28: Oncology Therapeutic Market, The US, Diagnosis Population, 2000-2015 47
• Figure 29: Oncology Therapeutic Market, The US, Prescription Population, 2000-2015 48
• Figure 30: Oncology Therapeutics Market, The US, Drivers and Restraints 48
• Figure 31: Oncology Therapeutics Market, Europe, Revenue Forecasts ($ m), 2000-2015 49
• Figure 32: Oncology Therapeutics Market, Europe, Volume Forecasts (million), 2000-2015 50
• Figure 33: Oncology Therapeutics Market, Europe, Average Cost per Dose ($), 2000-2015 51
• Figure 34: Oncology Therapeutics Market, Europe, Treatment Usage Patterns, 2000-2015 52
• Figure 35: Oncology Therapeutics Market, Europe, Diseased Population, 2000-2015 53
• Figure 36: Oncology Therapeutics Market, Europe, Treatment Seeking Population, 2000-2015 54
• Figure 37: Oncology Therapeutics Market, Europe, Diagnosis Population, 2000-2015 54
• Figure 38: Oncology Therapeutics Market, Europe, Prescription Population, 2000-2015 55
• Figure 39: Oncology Therapeutics Market, Europe, Drivers and Restraints, 2008-2015 56
• Figure 40: Oncology Therapeutics Market, Japan, Revenue ($ bn), 2000-2015 57
• Figure 41: Oncology Therapeutics Market, Japan, Volume Forecasts (million), 2000-2015 58
• Figure 42: Oncology Therapeutics Market, Japan, Average Cost per Dose ($), 2000-2015 59
• Figure 43: Oncology Therapeutics Market, Japan, Treatment Usage Patterns, 2000-2015 60
• Figure 44: Oncology Therapeutics Market, Japan, Diseased Population, 2000-2015 61
• Figure 45: Oncology Therapeutics Market, Japan, Treatment Seeking Population, 2000-2015 61
• Figure 46: Oncology Therapeutics Market, Japan, Diagnosis Population, 2000-2015 62
• Figure 47: Oncology Therapeutics Market, Japan, Prescription Population, 2000-2015 63
• Figure 48: Oncology Therapeutics Market, Global, Market Share of Major Indications, 2008 64
• Figure 49: Breast Cancer Therapeutics Market, Global, Revenue Forecasts ($ m), 2000-2015 67
• Figure 50: Breast Cancer Therapeutics Market, Global, Volume (million), 2000-2015 68
• Figure 51: Breast Cancer Therapeutics Market, Global, Average Cost per Dose ($), 2000-2015 69
• Figure 52: Breast Cancer Therapeutics Market – Major Drivers and Restraints – 2008-2015 70
• Figure 53: Breast Cancer Therapeutics Market, Global, Usage Patterns, 2000-2015 70
• Figure 54: Breast Cancer Therapeutics Market, Global, Diseased Population, 2008-2015 71
• Figure 55: Breast Cancer Therapeutics Market, Global, Treatment Seeking Population, 2000-2015 72
• Figure 56: Breast Cancer Therapeutics Market, Global, Diagnosis Population, 2000-2015 73
• Figure 57: Breast Cancer Therapeutics Market, Global, Prescription Population, 2000-2015 73
• Figure 58: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, Revenue Forecasts ($ m), 2000-2015 76
• Figure 59: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, Volume (million), 2000-2015 77
• Figure 60: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, Average Cost per Dose ($), 2000-2015 78
• Figure 61: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, Drivers and Restraints, 2008-2015 79
• Figure 62: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, Usage Patterns, 2000-2015 79
• Figure 63: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, Diseased Population, 2000-2015 80
• Figure 64: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, Treatment Seeking Population, 2000-2015 81
• Figure 65: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, Diagnosis Population, 2000-2015 81
• Figure 66: Non-Hodgkin’s Lymphoma Therapeutics Market, Global, Prescription Population, 2000-2015 82
• Figure 67: Colorectal Cancer Therapeutics Market, Global, Revenue Forecasts ($ m), 2000-2015 86
• Figure 68: Colorectal Cancer Therapeutics Market, Global, Volume (million), 2000-2015 87
• Figure 69: Colorectal Cancer Therapeutics Market, Global, Average Cost per Dose ($), 2000-2015 88
• Figure 70: Colorectal Cancer Therapeutics Market, Global, Drivers and Restraints, 89
• Figure 71: Colorectal Cancer Therapeutics Market, Global, Usage Patterns, 2000-2015 89
• Figure 72: Colorectal Cancer Therapeutics Market, Global, Diseased Population, 2000-2015 90
• Figure 73: Colorectal Cancer Therapeutics Market, Global, Treatment Seeking Population, 2000-2015 91
• Figure 74: Colorectal Cancer Therapeutics Market, Global, Diagnosis Population, 2000-2015 92
• Figure 75: Colorectal Cancer Therapeutics Market, Global, Prescription Population, 2000-2015 93
• Figure 76: Prostate Cancer Therapeutics Market, Global, Revenue ($m), 2000-2015 95
• Figure 77: Prostate Cancer Therapeutics Market, Global, Volume (million), 2000-2015 96
• Figure 78: Prostate Cancer Therapeutics Market, Global, Average Cost per Dose ($), 2000-2015 97
• Figure 79: Prostate Cancer Therapeutics Market, Major Drivers and Restraints, 2008-2015 98
• Figure 80: Prostate Cancer Therapeutics Market, Global, Usage Patterns, 2000-2015 99
• Figure 81: Prostate Cancer Therapeutics Market, Global, Diseased Population, 2000-2015 100
• Figure 82: Prostate Cancer Therapeutics Market, Global, Treatment Seeking Population, 2000-2015 100
• Figure 83: Prostate Cancer Therapeutics Market, Global, Diagnosis Population, 2000-2015 101
• Figure 84: Prostate Cancer Therapeutics Market, Global, Prescription Population, 2000-2015 102
• Figure 85: Lung Cancer Therapeutics Market, Global, Revenue ($ m), 2000-2015 106
• Figure 86: Lung Cancer Therapeutics Market, Global, Volume (million), 2000-2015 107
• Figure 87: Lung Cancer Therapeutics Market, Global, Average Cost per Dose ($), 2000-2015 108
• Figure 88: Lung Cancer Therapeutics Market – Major Drivers and Restraints – 2008-2015 109
• Figure 89: Lung Cancer Therapeutics Market, Global, Usage Patterns, 2000-2015 109
• Figure 90: Lung Cancer Therapeutics Market, Global, Diseased Population, 2000-2015 110
• Figure 91: Lung Cancer Therapeutics Market, Global, Treatment Seeking Population, 2000-2015 111
• Figure 92: Lung Cancer Therapeutics Market, Global, Diagnosis Population, 2000-2015 112
• Figure 93: Lung Cancer Therapeutics Market, Global, Prescription Population, 2000-2015 113
• Figure 94: Oncology Therapeutics Market, Global, R&D Pipeline (Number and %), September 2009 114
• Figure 95: Oncology Therapeutics Market, Global, Strategies for Successful Product Launches in Cancer Market 115
• Figure 96: Oncology Therapeutics Market, Global, Cancer Tumors Segmented by their Market and Degree of Unmet Needs 116
• Figure 97: Oncology Therapeutics Market, Global, Top Three Companies Landscape, 2008 133
• Figure 98: Oncology Therapeutics Market, Global, Top 10 Companies Sales ($ m), 2006-08 134
• Figure 99: Oncology Therapeutics Market, Global, R&D Pipeline (NCE) of the Top 10 Companies, 2009 135
• Figure 100: Oncology Therapeutics Market, Global, Key Target Therapies Launched, 1998-2009 136
• Figure 101: Oncology Therapeutics Market, Global, Market Trends 137
• Figure 102: Oncology Therapeutics Market, Global, Market Share Analysis, 2008 138
• Figure 103: Oncology Therapeutics Market, Global, Top 5 Companies Benchmarking, 2008 138
• Figure 104: Oncology Therapeutics Market, Global, Top 10 Brands’ Sales ($ m), 2006-08 139
• Figure 105: Oncology Therapeutics Market, Global, Roche Oncology Drugs Segmentation, 2008 140
• Figure 106: Oncology Therapeutics Market, Global, Roche/Genentech Sales, 2006-15 141
• Figure 107: Oncology Therapeutics Market, Global, Roche/Genentech, Number of Products in Clinical Trails by Indication, June 2009 145
• Figure 108: Oncology Therapeutics Market, Global, Roche/Genentech, Follow on Indications, June 2009 146
• Figure 109: Oncology Therapeutics Market, Global, Roche/Genentech, Phase-wise Analysis, June 2009 147
• Figure 110: Oncology Therapeutics Market, Global, Novartis, Sales ($ m), 2006-15 148
• Figure 111: Oncology Therapeutics Market, Global, Novartis, R&D Pipeline by Indication, June 2009 151
• Figure 112: Oncology Therapeutics Market, Global, Novartis, R&D Pipeline Phase-wise Analysis, June 2009 152
• Figure 113: Oncology Therapeutics Market, Global, Sanofi Aventis, Sales Segmentation by Brand ($ m) – 2008 154
• Figure 114: Oncology Therapeutics Market, Global, Sanofi-Aventis, Sales ($ m), 2006-15 155
• Figure 115: Oncology Therapeutics Market, Global, Sanofi-Aventis, R&D Pipeline by Indication, June 2009 156
• Figure 116: Oncology Therapeutics Market, Global, Sanofi-Aventis, R&D Pipeline by Phase, June 2009 158
• Figure 117: Oncology Therapeutics Market, Global, Amgen, Sales Segmentation by Brand, 2008 159
• Figure 118: Oncology Therapeutics Market, Global, Amgen, Sales ($ m), 2006-15 160
• Figure 119: Oncology Therapeutics Market, Global, R&D Pipeline by Indication, June 2009 162
• Figure 120: Oncology Therapeutics Market, Global, Amgen, R&D Pipeline by Phase, June 2009 163
• Figure 121: Oncology Therapeutics Market, Global, AstraZeneca, Sales Segmentation by Brand, 2008 164
• Figure 122: Oncology Therapeutics Market, Global, AstraZeneca, Sales ($ m), 2006-2015 165
• Figure 123: Oncology Therapeutics Market, Global, R&D Pipeline by Indication, June 2009 167
• Figure 124: Oncology Therapeutics Market, Global, AstraZeneca, R&D Pipeline by Phase, June 2009 167
• Figure 125: Oncology Therapeutics Market, Global, Major M&A Deals, 2008-09 169
• Figure 126: Oncology Therapeutics Market, Global, Major Licensing Agreements By Each Phase, 2008-09 171
• Figure 127: Oncology Therapeutics Market, Global, Major Licensing Agreements By Geography, 2008-09 172
• Figure 128: Oncology Therapeutics Market, Global, Major Licensing Agreements By Type, 2008-09 172
• Figure 129: Oncology Therapeutics Market, Global, Major Licensing Agreements By Value, 2008-09 173
• Figure 130: Research Methodology 181

Other users found this report page using the following search terms: lung cancer breast cancer prostate cancer colorectal cancer Non-Hodgkin’s Lymphoma oncology market cancer future forecasts therapeutics treatment trends europe prostate

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.